Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 6/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 4/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 4/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27188819 | 1.00 | SCN9A (0.39) | SCN9ASCN2ASCN10AKCNH2SCN5A | |
| SCHEMBL23143258 | 0.91 | GAA (0.37) | SCN9ASCN2ASCN10AKCNH2SCN5A | |
| SCHEMBL29766286 | 0.91 | GAA (0.37) | SCN9ASCN2ASCN10AKCNH2SCN5A | |
| SCHEMBL27188852 | 0.88 | SCN9A (0.39) | SCN9ASCN2ASCN10AKCNH2SCN5A | |
| SCHEMBL29896098 | 0.88 | SCN9A (0.39) | SCN9ASCN2ASCN10AKCNH2SCN5A | |
| SCHEMBL27188849 | 0.84 | PIK3CA (0.42) | SCN2ASCN10AGAAROCK2HSD17B13 | |
| SCHEMBL29896176 | 0.84 | PIK3CA (0.42) | SCN2ASCN10AGAAROCK2HSD17B13 | |
| SCHEMBL29896099 | 0.82 | SCN9A (0.39) | SCN9ASCN2ASCN10AEPHX2ALDH1A1 | |
| SCHEMBL23143259 | 0.82 | SCN9A (0.39) | SCN9ASCN2ASCN10AEPHX2ALDH1A1 | |
| SCHEMBL29896172 | 0.81 | MAPT (0.41) | SCN2ASCN10AKCNH2SCN5AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952344-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-04-09 | — | — | US | disclosed |
| US-20220340527-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340527-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2A, GRIN2B | SCN9A 131/4885SCN2A 31/4885SCN10A 29/4885 |
| US-11952344-B2 | Heterocyclic compound and use thereof | GRIN1, GRIN2A, GRIN2B | SCN9A 131/4885SCN2A 31/4885SCN10A 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.